Antimicrobial use, drug-resistant infections and COVID-19

Timothy M Rawson; Damien Ming; Raheelah Ahmad; Luke S P Moore; Alison H Holmes

doi:10.1038/s41579-020-0395-y

Antimicrobial use, drug-resistant infections and COVID-19

Nat Rev Microbiol. 2020 Aug;18(8):409-410. doi: 10.1038/s41579-020-0395-y.

Authors

Timothy M Rawson¹, Damien Ming¹, Raheelah Ahmad¹, Luke S P Moore¹, Alison H Holmes²

Affiliations

¹ Imperial College London, South Kensington, London, UK.
² Imperial College London, South Kensington, London, UK. [email protected].

Abstract

Coronavirus disease 2019 may have a complex long-term impact on antimicrobial resistance (AMR). Coordinated strategies at the individual, health-care and policy levels are urgently required to inform necessary actions to reduce the potential longer-term impact on AMR and on access to effective antimicrobials.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-Infective Agents / administration & dosage
Anti-Infective Agents / standards*
Anti-Infective Agents / supply & distribution
Antimicrobial Stewardship / standards*
Antimicrobial Stewardship / trends
Bacterial Infections / drug therapy
Bacterial Infections / microbiology
COVID-19
Coronavirus Infections / drug therapy
Drug Prescriptions / statistics & numerical data*
Drug Resistance, Microbial*
Health Policy / trends*
Humans
Pandemics / statistics & numerical data*
Pneumonia, Viral / drug therapy
Public Health / statistics & numerical data

Substances

Anti-Infective Agents